Home » Topics » Substance use and poisoning, BioWorld Science

Substance use and poisoning, BioWorld Science
RSS

FDA decides not to approve Indivior's naloxone nasal spray for opioid overdose

Nov. 25, 2015

TRIA Bioscience presents synthetic hapten vaccines

Nov. 23, 2015

First FDA approval of naloxone nasal spray for opioid overdose

Nov. 19, 2015

FDA grants fast track designation to long-acting buprenorphine for opioid addiction

Nov. 5, 2015

FDA grants fast track designation to Insys' sublingual naloxone for opioid overdose

Oct. 30, 2015

U.S. and Italian team reports development of FAAH inhibitors

Oct. 29, 2015

NIAID awards SRI International contract to develop treatments for radiation exposure

Oct. 16, 2015

Addex Therapeutics reports efficacy of ADX-71441 in models of alcohol use disorder

Oct. 14, 2015

Pluristem and FDA agree development pathway for PLX-R18 in ARS

Sep. 21, 2015

Department of Defense awards Cleveland BioLabs contract for development of entolimod

Sep. 7, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...